Finance

Lists
Why is CBIO up 5,59%?
Dive Deeper
CBIO:NASDAQ
Crescent Biopharma Inc
14,91 USD
+5,59%
(+0,79) 1D
9-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
14,07 USD
High
15,28 USD
Low
14,07 USD
Mkt. cap
553,82 млн
Avg. vol.
493,84 миң
Volume
1,00
52-wk high
27,41 USD
52-wk low
8,72 USD
EPS
-7,41 USD
Beta
1,27
Shares outstanding
37,14 млн
No. of employees
69
Open
14,07 USD
High
15,28 USD
Low
14,07 USD
Mkt. cap
553,82 млн
Avg. vol.
493,84 миң
Volume
1,00
52-wk high
27,41 USD
52-wk low
8,72 USD
EPS
-7,41 USD
Beta
1,27
Shares outstanding
37,14 млн
No. of employees
69
News stories
From web sources and news partners
About Crescent Biopharma Inc
CEO-
Employees69
Founded2024
HeadquartersУолтем, Массачусетс, Америка Кошмо Штаттары
Sector-
Websitecrescentbiopharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to CBIO in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current 14,91 USD
36,00 USD (+141,45%)
Average
29,75 USD (+99,53%)
Lowest
27,00 USD (+81,09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Willey
Stifel Nicolaus
Buy
Maintained
28,00 USD
+87,8%
10/06/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Upgraded
36,00 USD
+141,4%
10/06/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
28,00 USD
+87,8%
10/05/2026
Robert Driscoll
Wedbush
Buy
Maintained
27,00 USD
+81,1%
09/14/2026
Unknown Analyst
Wedbush
Buy
Maintained
27,00 USD
+81,1%
09/14/2026
Biren Amin
Piper Sandler
Buy
Maintained
35,00 USD
+134,7%
06/23/2026
Bradley Canino
Guggenheim
Buy
Maintained
35,00 USD
+134,7%
04/29/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
10,84 млн
1,04 млн
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
20,35 млн
95,03 млн
17,90 млн
19,39 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,54 млн
7,31 млн
7,86 млн
8,74 млн
Operating expense
25,88 млн
102,34 млн
25,77 млн
28,13 млн
Total operating expenses
25,88 млн
102,34 млн
25,77 млн
28,13 млн
Operating income
-25,88 млн
-91,49 млн
-24,73 млн
-28,13 млн
Other non operating income
-
-
-
-
EBT including unusual items
-24,61 млн
-90,40 млн
-23,28 млн
-24,84 млн
EBT excluding unusual items
-24,61 млн
-90,40 млн
-23,28 млн
-26,61 млн
Income tax expense
-
2,00 млн
-
-
Effective tax rate
-
-2,21%
-
-
Other operating expenses
-
-
-
-
Net income
-24,61 млн
-92,40 млн
-23,28 млн
-24,84 млн
Net profit margin
-
-852,06%
-2 240,90%
-
Earnings per share
-1,37
-4,92
-0,70
-0,62
Interest and investment income
1,28 млн
1,10 млн
1,45 млн
1,53 млн
Interest expense
-
-
-
-
Net interest expenses
1,28 млн
1,10 млн
1,45 млн
1,53 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-25,86 млн
-91,44 млн
-24,66 млн
-28,07 млн
Gain or loss from assets sale
-
-
-
-1,77 млн
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору